Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients

Abstract
EPIDEMIOLOGICAL data demonstrate that perioperative and postoperative venous thrombosis are common in high-risk patients undergoing surgery.1-5 In the absence of thromboprophylaxis, this disorder occurs in 40% to 60% of patients receiving hip implants.5,6 Prophylactic recommendations against venous thromboembolism in patients undergoing hip arthroplasty include warfarin sodium and subcutaneous low-molecular-weight heparin therapy.5,6

This publication has 23 references indexed in Scilit: